Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester, discusses insights from the FLAME trial analysis and the ICS-RECODE meta-analysis.

which was reported at last year's ERS and showed that withdrawing the steroid component from triple therapy with LAMA/LABA/ICS had no impact on exacerbation rates in COPD. That trial was not ...

Expert Rev Resp Med. 2013;7(3):307-320. Although efficacy differences between LABA/ICS and ICS alone are probably minimal in treating mild persistent asthma, healthcare providers more frequently ...

SecurityWeek’s 2024 ICS Cybersecurity Conference kicks off today at the InterContinental Hotel Buckhead Atlanta. With 80+ sessions over three days, the conference brings together hundreds of critical ...